Starting to feel like Big Pharma is trying to push us
Starting to feel like Big Pharma is trying to push us down... by losing money. But, in their eyes less than they stand to lose.
The problem is, the science is unaffected by the share price. Investors are affected. Some will sell out of fear.
But the march will continue. Obviously an EUA changes everything. But, if we dont get it, and have to continue our trials, there is still a reckoning coming.
SP may dip. Worst case we are stuck on OTC for another two months while we finish the trials.
We have the means to finish our COVID trials. Thousand more will die, but we will finish.
When we get an approval, whether its 2 days or 2 months, the share price will rise to the level that it should be at. (IMO)
3
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Understanding GTT's Share Capital and Voting Rights In the realm of corporate governance, transparency regarding voting rights and shares plays a crucial role in building trust among investors. This month, we delve into the comprehensive details regarding the total number of shares and voting rights for GTT. Key Disclosure Details This important monthly disclosure...
Continue Reading
Anticipating Revenue Growth at Go North Hemp Go North Hemp, a prominent wholesale supplier of hemp-derived ingredients, has announced its ambitious projection for the year 2025: a remarkable 100% year-over-year revenue increase compared to 2024. This growth is attributed to the rising consumer demand for its innovative range of products, including EPN (Euphorinol), CBG,...
Continue Reading
Ezee Fiber's Major Expansion into New Markets Ezee Fiber, renowned for delivering high-speed multi-gig internet services, has recently announced an investment of over $400 million aimed at expanding its fiber-to-the-premises network. This exciting development will see the company's services reaching more homes and businesses across the Greater Puget Sound region. The CEO...
Continue Reading
John Hancock Preferred Income II Reaches New Milestone In an impressive display of resilience, John Hancock Preferred Income II (HPF) stock has reached a remarkable 52-week high, currently trading at $18.88 USD. This new peak is significant, reflecting a substantial 36.5% change in the stock's price over the year. The sharp increase in value indicates heightened investor...
Continue Reading
Federal Reserve's Transformative Rate Decision Recent activity in the financial markets has captured the attention of both investors and analysts. Following the Federal Reserve's choice to cut interest rates by 0.5%, we're starting to see significant changes in market dynamics. This reduction initiates a much-anticipated rate-cutting cycle, which could influence the...
Continue Reading
